207940.KS — Samsung Biologics to acquire Switzerland's PolyPeptide in $1.8B cash deal

Samsung Biologics has agreed to acquire Swiss contract drug manufacturer PolyPeptide Group AG for approximately $1.8 billion in an all-cash transaction. The deal, valued at 1.46 billion Swiss francs, is aimed at expanding Samsung Biologics' manufacturing capabilities and strengthening its position in the global pharmaceutical market.